These neuroendocrine adjustments re-establish a balanced LH/FSH ratio, attenuate ovarian androgen synthesis, and ultimately improve menstrual regularity and ovarian function in PCOS patients (36). The gene discussed is BRD2; the disease is polycystic ovary syndrome.